In addition, PEGylation reduces the clearance of protein drugs by reticuloendothelial tissue, shields antigenic determinants, reduces immune system recognition, and prevents degradation by proteolytic enzymes
Data from the PIONEER (Peptide Innovation for Oral Delivery of Semaglutide in Type 2 Diabetes) trials (NCT03018028 and NCT03015220) indicated that oral semaglutide also led to dose-dependent weight loss in both younger and older adult groups, but body composition was not assessed [57]
BPC-157 research demonstrates benefits across multiple tissue types: bone, muscle, tendon, ligament, and connective tissue
Most common side effects are gastrointestinal such as mild nausea, soft stools or diarrhea
described as transient Nausea community sources most commonly report this in the first 2-3 injections, described as dose-dependent Headache occasionally self-reported